"Antibodies, Monoclonal" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Antibodies produced by a single clone of cells.
| Descriptor ID |
D000911
|
| MeSH Number(s) |
D12.776.124.486.485.114.224 D12.776.124.790.651.114.224 D12.776.377.715.548.114.224
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Antibodies, Monoclonal".
Below are MeSH descriptors whose meaning is more specific than "Antibodies, Monoclonal".
This graph shows the total number of publications written about "Antibodies, Monoclonal" by people in this website by year, and whether "Antibodies, Monoclonal" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 3 | 1 | 4 |
| 1996 | 2 | 3 | 5 |
| 1997 | 2 | 2 | 4 |
| 1998 | 2 | 0 | 2 |
| 1999 | 2 | 0 | 2 |
| 2000 | 2 | 1 | 3 |
| 2001 | 2 | 2 | 4 |
| 2002 | 1 | 2 | 3 |
| 2003 | 4 | 2 | 6 |
| 2004 | 3 | 3 | 6 |
| 2005 | 6 | 3 | 9 |
| 2006 | 2 | 6 | 8 |
| 2007 | 5 | 2 | 7 |
| 2008 | 6 | 5 | 11 |
| 2009 | 4 | 1 | 5 |
| 2010 | 3 | 3 | 6 |
| 2011 | 2 | 3 | 5 |
| 2012 | 1 | 1 | 2 |
| 2013 | 1 | 1 | 2 |
| 2015 | 1 | 1 | 2 |
| 2016 | 2 | 1 | 3 |
| 2017 | 2 | 1 | 3 |
| 2018 | 2 | 0 | 2 |
| 2019 | 0 | 1 | 1 |
| 2020 | 2 | 0 | 2 |
| 2021 | 1 | 1 | 2 |
| 2022 | 2 | 2 | 4 |
| 2023 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Antibodies, Monoclonal" by people in Profiles.
-
Efficacy and safety of iscalimab, a novel anti-CD40 monoclonal antibody, in moderate-to-severe myasthenia gravis: A phase 2 randomized study. J Clin Neurosci. 2024 Jan; 119:76-84.
-
Humoral Immunity After COVID-19 Vaccination in Chronic Lymphocytic Leukemia and Other Indolent Lymphomas: A Single-Center Observational Study. Oncologist. 2023 10 03; 28(10):e930-e941.
-
Bispecific antibodies targeting CTLA-4: game-changer troopers in cancer immunotherapy. Front Immunol. 2023; 14:1155778.
-
Impact of early relapse within 24?months after first-line systemic therapy (POD24) on outcomes in patients with marginal zone lymphoma: A US multisite study. J Hematol Oncol. 2023 05 08; 16(1):49.
-
Improved control of SARS-CoV-2 by treatment with a nucleocapsid-specific monoclonal antibody. J Clin Invest. 2022 12 01; 132(23).
-
Advances in therapeutic targeting of immune checkpoints receptors within the CD96-TIGIT axis: clinical implications and future perspectives. Expert Rev Clin Immunol. 2022 Dec; 18(12):1217-1237.
-
Efficacy and Safety of TRC105 Plus Pazopanib vs Pazopanib Alone for Treatment of Patients With Advanced Angiosarcoma: A Randomized Clinical Trial. JAMA Oncol. 2022 05 01; 8(5):740-747.
-
Implementation of a Collaborated Antimicrobial Stewardship Program and Outpatient Parenteral Antimicrobial Therapy (OPAT) Unit-driven Monoclonal Antibody Therapy Program for COVID-19 at an NYC Hospital. Int J Infect Dis. 2022 May; 118:214-219.
-
Regression of Triple-Negative Breast Cancer in a Patient-Derived Xenograft Mouse Model by Monoclonal Antibodies against IL-12 p40 Monomer. Cells. 2022 01 13; 11(2).
-
18F-FDG PET/CT Imaging Features of Cardiac Arrhythmia in a Patient Treated with Panitumumab. J Nucl Med Technol. 2021 Dec; 49(4):360-361.